Login
Ricerca |
JOURNAL TOOLS |
| Opzioni di pubblicazione |
| eTOC |
| Per abbonarsi PROMO |
| Sottometti un articolo |
| Segnala alla tua biblioteca |
ARTICLE TOOLS |
| Publication history |
| Estratti |
| Permessi |
| Per citare questo articolo |
| Share |
I TUOI DATI
I TUOI ORDINI
CESTINO ACQUISTI
N. prodotti: 0
Totale ordine: € 0,00
COME ORDINARE
I TUOI ABBONAMENTI
I TUOI ARTICOLI
I TUOI EBOOK
COUPON
ACCESSIBILITÀ
REVIEW
Panminerva Medica 2018 December;60(4):174-84
DOI: 10.23736/S0031-0808.18.03542-5
Copyright © 2018 EDIZIONI MINERVA MEDICA
lingua: Inglese
Therapy for relapsed multiple myeloma
Mohammed A. ALJAMA, M. Hasib SIDIQI, David DINGLI ✉
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Despite significant progress in our understanding and the development of novel therapies, most patients with multiple myeloma will experience relapse of their disease. Therapy of relapsed myeloma has improved due to the availability of novel agents that are highly active against the disease. However, the selection of therapy can be challenging due to the emergence of toxicities, comorbidities and frailty. In the following we discuss our approach to the treatment of the patient with relapsed myeloma.
KEY WORDS: Recurrence - Multiple myeloma - Therapeutics
